SOME ASPECTS OF IMPROVING ADHERENCE TO DUAL ANTITHROMBOTIC THERAPY AFTER ACUTE CORONARY SYNDROME
The current clinical guidelines for the treatment of patients with acute coronary syndrome (ACS) claim that simultaneous use of two drugs that inhibit platelet activity is mandatory for most patients. This approach known as dual antiplatelet therapy (DAT), in view of the similarity of the mechanisms...
Main Author: | A. D. Erlikh |
---|---|
Format: | Article |
Language: | Russian |
Published: |
«REMEDIUM GROUP» Ltd.
2017-05-01
|
Series: | Атеротромбоз |
Subjects: | |
Online Access: | https://www.aterotromboz.ru/jour/article/view/108 |
Similar Items
-
Adherence of ticagrelOr in real world patients with aCute coronary syndrome: The AD-HOC study
by: Luigi Fiocca, et al.
Published: (2022-10-01) -
Efficacy and Safety of Prolonged Dual Antiplatelet Therapy after Percutaneous Coronary Intervention in Acute Coronary Syndrome Patients
by: Jialun Han, et al.
Published: (2023-03-01) -
Early discontinuation of dual antiplatelet therapy via acetylsalicylic acid cessation in patients with acute coronary syndrome undergoing percutaneous coronary interventions to reduce the bleeding risk
by: O. V. Averkov
Published: (2021-02-01) -
Choice of dual antiplatelet therapy in patients with acute coronary syndrome after percutaneous coronary intervention
by: A. N. Golosova, et al.
Published: (2020-08-01) -
Dual antiplatelet therapy for reduction in mortality in patients with acute and chronic coronary syndromes
by: Maciej Lesiak, et al.
Published: (2021-12-01)